JP4709471B2 - 低酸素の細胞および組織を標的としたウイルス - Google Patents

低酸素の細胞および組織を標的としたウイルス Download PDF

Info

Publication number
JP4709471B2
JP4709471B2 JP2002530023A JP2002530023A JP4709471B2 JP 4709471 B2 JP4709471 B2 JP 4709471B2 JP 2002530023 A JP2002530023 A JP 2002530023A JP 2002530023 A JP2002530023 A JP 2002530023A JP 4709471 B2 JP4709471 B2 JP 4709471B2
Authority
JP
Japan
Prior art keywords
gene
hypoxia
cells
virus
hif
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002530023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004509635A5 (enExample
JP2004509635A (ja
Inventor
メイアー， アーウィン ヴァン
アインスレー シー． ニコルソン，
ドーン イー． ポスト，
Original Assignee
エモリー ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エモリー ユニバーシティー filed Critical エモリー ユニバーシティー
Publication of JP2004509635A publication Critical patent/JP2004509635A/ja
Publication of JP2004509635A5 publication Critical patent/JP2004509635A5/ja
Application granted granted Critical
Publication of JP4709471B2 publication Critical patent/JP4709471B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2002530023A 2000-09-26 2001-09-26 低酸素の細胞および組織を標的としたウイルス Expired - Fee Related JP4709471B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23528300P 2000-09-26 2000-09-26
US60/235,283 2000-09-26
PCT/US2001/030236 WO2002026192A2 (en) 2000-09-26 2001-09-26 Viruses targeted to hypoxic cells and tissues

Publications (3)

Publication Number Publication Date
JP2004509635A JP2004509635A (ja) 2004-04-02
JP2004509635A5 JP2004509635A5 (enExample) 2008-09-11
JP4709471B2 true JP4709471B2 (ja) 2011-06-22

Family

ID=22884861

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002530023A Expired - Fee Related JP4709471B2 (ja) 2000-09-26 2001-09-26 低酸素の細胞および組織を標的としたウイルス

Country Status (7)

Country Link
EP (1) EP1328291B1 (enExample)
JP (1) JP4709471B2 (enExample)
AT (1) ATE418342T1 (enExample)
AU (2) AU9479301A (enExample)
CA (1) CA2423833C (enExample)
DE (1) DE60137137D1 (enExample)
WO (1) WO2002026192A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2501010A1 (en) * 2002-10-01 2004-04-15 Duke University Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors
US20040142558A1 (en) 2002-12-05 2004-07-22 Granneman Ernst H. A. Apparatus and method for atomic layer deposition on substrates
US7601223B2 (en) 2003-04-29 2009-10-13 Asm International N.V. Showerhead assembly and ALD methods
US7537662B2 (en) 2003-04-29 2009-05-26 Asm International N.V. Method and apparatus for depositing thin films on a surface
US20080077999A1 (en) * 2004-03-23 2008-03-27 Eisai R&D Management Co., Ltd. Using Nonhuman Animal Model, Method of Measuring Transcription Activity Method of Measuring Cell Quantity and Method of Measuring Tumor Volume
US8487087B2 (en) 2005-03-11 2013-07-16 Oriental Yeast Co., Ltd. Model animal in which state of disease condition is observable in real time, gene construct for achieving the same and use of the same
CN108623693B (zh) * 2017-03-20 2022-03-25 徐寒梅 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用
CN116064675B (zh) * 2022-07-22 2024-12-03 西安电子科技大学 一种重组质粒、重组慢病毒载体、稳转细胞系及其构建方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783435A (en) * 1996-08-06 1998-07-21 Lamparski; Henry G. Prostate cancer drug screenings
CA2308575A1 (en) * 1997-11-03 1999-05-14 Tom Tsang Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
US6900049B2 (en) * 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof

Also Published As

Publication number Publication date
WO2002026192A3 (en) 2002-08-08
DE60137137D1 (de) 2009-02-05
EP1328291A4 (en) 2005-07-06
JP2004509635A (ja) 2004-04-02
AU9479301A (en) 2002-04-08
EP1328291B1 (en) 2008-12-24
EP1328291A2 (en) 2003-07-23
ATE418342T1 (de) 2009-01-15
WO2002026192A2 (en) 2002-04-04
AU2001294793B2 (en) 2006-06-29
CA2423833A1 (en) 2002-04-04
CA2423833C (en) 2011-02-22

Similar Documents

Publication Publication Date Title
JP6375273B2 (ja) 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体
US7048920B2 (en) Recombinant oncolytic adenovirus for human melanoma
EP1002103B1 (en) A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
CA2836987C (en) Chimeric adenoviruses for use in cancer treatment
US7575919B2 (en) Adenovirus vectors containing cell status-specific response elements and methods of use thereof
JP2007525949A (ja) 自己プロセッシング性ペプチド切断部位を含む細胞特異的複製適格ウィルス・ベクター
WO2012163119A1 (zh) 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
Kim et al. Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in α-fetoprotein-producing human liver cancer cells
JP4709471B2 (ja) 低酸素の細胞および組織を標的としたウイルス
JP2004509635A5 (enExample)
EP1071805B1 (en) Adenoviral vectors for treating disease
US7285414B2 (en) Viruses targeted to hypoxic cells and tissues
AU2001294793A1 (en) Viruses targeted to hypoxic cells and tissues
Sonabend et al. Oncolytic adenoviral therapy for glioblastoma multiforme
US20040101825A1 (en) Viruses targeted to hypoxic cells and tissues
US20060275262A1 (en) Conditionally replicating viruses and methods for cancer virotherapy
WO2025159067A1 (ja) 腫瘍溶解性ウイルス及びそれを用いたがん治療
AU2005337612A1 (en) Conditionally replicating viruses and methods for cancer virotherapy
Kastberger Creating universality for cancer gene therapy in applying Adenovirus vectors with altered tropism: designing Adenovirus particles using K-Coil/E-Coil technology to control receptor specificity

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071105

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20080725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110120

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110318

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees